Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:10:17 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:EDIT from 2023-05-04 to 2024-05-03 - 32 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 07:00U:EDITNews ReleaseEditas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
2024-05-01 08:00U:EDITNews ReleaseEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
2024-04-22 16:31U:EDITNews ReleaseEditas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
2024-02-28 07:00U:EDITNews ReleaseEditas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
2024-02-21 07:00U:EDITNews ReleaseEditas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
2024-01-31 09:00U:EDITNews ReleaseEditas Medicine to Participate in Upcoming Investor Conferences
2024-01-08 08:15U:EDITNews ReleaseEditas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
2024-01-03 07:00U:EDITNews ReleaseEditas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 09:00U:EDITNews ReleaseEditas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
2023-12-11 12:00U:EDITNews ReleaseEditas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
2023-11-03 07:00U:EDITNews ReleaseEditas Medicine Announces Third Quarter 2023 Results and Business Updates
2023-11-02 09:12U:EDITNews ReleaseEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
2023-10-27 07:00U:EDITNews ReleaseEditas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
2023-10-16 08:00U:EDITNews ReleaseEditas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
2023-09-25 16:30U:EDITNews ReleaseEditas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
2023-09-25 09:00U:EDITNews ReleaseEditas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
2023-08-30 09:00U:EDITNews ReleaseEditas Medicine Announces Upcoming Investor Events
2023-08-28 07:01U:EDITNews ReleaseMedicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
2023-08-02 07:00U:EDITNews ReleaseEditas Medicine Announces Second Quarter 2023 Results and Business Updates
2023-07-27 09:00U:EDITNews ReleaseEditas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
2023-07-27 09:00U:EDITNews ReleaseEditas Medicine and Azzur Group Expand Partnership to Accelerate Editas ¢ € ™ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
2023-07-26 07:00U:EDITNews ReleaseEditas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
2023-07-25 08:00U:EDITNews ReleaseEditas Medicine Reports Inducement Grant to New Chief Scientific Officer
2023-07-24 07:00U:EDITNews ReleaseEditas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
2023-06-14 22:07U:EDITNews ReleaseEditas Medicine Announces Pricing of Offering of Common Stock
2023-06-14 16:05U:EDITNews ReleaseEditas Medicine Announces Offering of Common Stock
2023-06-09 03:00U:EDITNews ReleaseEditas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
2023-06-06 08:00U:EDITNews ReleaseEditas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
2023-05-18 16:30U:EDITNews ReleaseEditas Medicine Reports Inducement Grant to New Chief Financial Officer
2023-05-16 16:30U:EDITNews ReleaseEditas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
2023-05-11 10:33U:EDITNews ReleaseEditas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
2023-05-05 07:00U:EDITNews ReleaseEditas Medicine Announces First Quarter 2023 Results and Business Updates